Contact this trialFirst, we need to learn more about you.
SGLT2 Inhibition for High-Risk Prostate Cancer
Recruiting1 awardPhase 1
Saint Louis, Missouri
This trial is testing if dapagliflozin, a diabetes drug, is safe and well-tolerated for patients with advanced prostate cancer. The medication helps lower blood sugar by making the kidneys remove it through urine.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service